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Abstract
Background: Evidence for policy- and decision-making related to the cost of delivering tuberculosis (TB) control is lacking in
Ethiopia. We aimed to determine the cost and cost-effectiveness of involving health extension workers (HEWs) in TB
treatment under a community-based initiative in Ethiopia. This paper presents an ancillary cost-effectiveness analysis of
data from a RCT, from which the main outcomes have already been published.
Methodology/Principal Findings: Options of treating TB patients in the community by HEWs in the health posts and
general health workers at health facility were compared in a community-randomized trial. Costs were analysed from a
societal perspective in 2007 in US dollars using standard methods. We prospectively enrolled smear-positive patients, and
calculated the cost-effectiveness in terms of the cost per patient successfully treated. The total cost for each successfully
treated smear-positive patient was higher in health facilities (US$161.9) compared with the community-based approach
(US$60.7). The total, patient and care giver costs of community-based treatment were lower than health facility DOT by
62.6%, 63.9% and 88.2%, respectively. Involving HEWs added a total cost of US$8.80 to the health service per patient treated
in the health posts in the community.
Conclusions/Significance: Community-based treatment by HEWs costs only 37% of what treatment by general health
workers costs for similar outcomes. Involving HEWs in TB treatment is a cost-effective treatment alternative to the health
service and to the patients and their caregivers. Therefore, there is both an economic and public health reason to consider
involving HEWs in TB treatment in Ethiopia. However, community-based treatment would require initial investment for
implementation, training and supervision.
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Introduction
Ethiopia has one of the highest tuberculosis (TB) burdens in
the world [1]. Directly observed treatment short course (DOTS),
the World Health Organization (WHO) recommended TB
control strategy, was started in 1995 in Ethiopia by the National
TB and Leprosy Control Programme (NTLCP), being decen-
tralized to hospitals and health centres [2]. However, less than
half of the population has access to the health service [3]. Thus,
many TB patients remain undiagnosed, untreated and continue
transmitting the infection. The interaction between TB and
human immunodeficiency virus (HIV) infection has fuelled the
TB burden and affected the already overstretched health service,
which needs alternative ways of making the service accessible
[4].
Under the NTLCP, there are three levels of function for
coordinating TB control in hospitals and health centres: regions,
zones and districts. TB diagnosis and treatment is provided by
general health workers (GHWs) in health facilities [5]. The
treatment success rate (TSR) of smear-positive cases in the study
area was 76% (unpublished three year review of TB programme
performance in the study area), while 84% at the National level.
The case detection rate (CDR) of smear-positive cases was 41% in
the study area and 27% at the National level, far below the target
of 70%. However, the cost implication for the health service and
the community has not been estimated.
In 2004, the Government of Ethiopia launched a community-
based initiative focused on disease prevention and health
promotion to ensure equitable access to health service. To this
end, health extension workers (HEWs) were trained and deployed
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to each kebele (the lowest administrative unit in Ethiopia) to
provide health service. The HEWs function from an operational
unit - a health post in each kebele, receiving training on TB as
part of communicable disease prevention and control [6].
However, community DOTS was not yet implemented and
HEWs were not providing directly observed treatment (DOT) to
TB patients [5].
Studies show that involving community health workers in TB
control is cost-effective in improving the treatment success
compared with health facility-based DOTS [7,8,9,10,11,12,
13,14,15]. Community DOTS requires supervision, some initial
investment and a well-coordinated TB control programme. Its
effectiveness therefore depends on how well the health system
functions in coordination with the community [16].
We conducted a community randomized trial (CRT) in
Southern Ethiopia to determine whether involving HEWs in TB
control would improve smear-positive CDR and TSR compared
with health facility-based TB treatment. We found both improved
CDR (122% vs. 69%, p,0?001) and TSR (89% vs 83%, p= 0?012)
in the community-based DOT (CDOT) compared with the health
facility-based DOT (HFDOT) [17]. Therefore, determining
whether involving a community-based approach is also more
cost-effective would seem a relevant issue for policy- and decision
making. To our knowledge, there have been no studies of cost and
cost-effectiveness of alternative ways of treating TB in Ethiopia. In
this study, we aimed to determine the cost and cost-effectiveness of
involving HEWs in TB treatment in Southern Ethiopia. This
paper presents an ancillary cost-effectiveness analysis of data from
a RCT, from which the main outcomes have already been
published.
Methods
The protocol for this trial and supporting CONSORT checklists
are available as supporting information; see Checklist S1,
Flowchart S1 and Protocol S1. Full description of trial method-
ology is given in the paper reporting main trial findings [17].
Briefly, two treatment options of treating smear-positive patients
were compared: health facility and community DOT (CDOT - the
intervention).
Health Facility-Based DOT (HFDOT)
TB patients receive treatment under the direct observation of
GHWs in hospitals and health centres. They visit health facilities
daily for two months during the intensive phase. During the
continuation phase, patients visit health facilities once a month to
collect drugs but take the drugs unsupervised.
Community DOT (CDOT): The Intervention
TB patients visit the health post daily for two months during the
intensive phase to receive treatment under the direct observation
of HEWs in their kebele. During the continuation phase, patients
collect drugs from the HEWs on a monthly basis.
Trained HEWs and GHWs prospectively collected the cost data
by using a structured questionnaire. GHWs also used a checklist to
observe the conduct of DOT in the health facilities and the
kebeles.
Costing
Costs were assessed from a societal perspective in 2007 in US
dollars, using recommended standard methods [18]. We classified
costs in to programme and patient costs. Direct cost refers to
patient’s out-of-pocket expenses for seeking treatment, while
indirect cost refers to the cost of the time spent by the patient or
their caregivers or freed by the programme. Weighted mean cost
was calculated to costs related to patients and caregivers. In this
study, hereafter, cost values refer to mean cost values per
successfully treated smear-positive TB patient.
Programme costs. Programme costs are the health service
costs including the expenses required to establish the health
service, and run the TB programme in the districts and health
facilities including the health posts in the kebeles. The average cost
for each component of treatment (drugs, sputum examination,
treatment and other medical expenses) was calculated from the
quantity and unit prices of resources. Time costs were estimated
from the health facility providing DOT to the patient’s place of
residence. Joint costs (cost items shared by two or more services)
were allocated to TB patients based on the proportion of the total
health facility visits which they accounted for and the associated
health workers time. Annuitization was done on the basis of the
expected useful life of 30 years for buildings, 10 years for cars and
equipment and 5 years for motorcycles [19]. The base year for
valuing costs was 2007, and the exchange rate was 8.6 Ethiopian
Birr to US $1.
The cost of HEWs, part of the health service, included the time
spent for treatment supervision in the kebele, travel time and
expenditures associated with visits to the health facilities to collect
drugs. The time costs were converted to a monetary value based
on the monthly income of HEWs in US dollars. The cost of
training and supervision was also included.
Patient costs. Patient costs include the costs related to the
TB patient and their caregiver. The costs were estimated for the
smear-positive patients and their caregivers using a structured
questionnaire. TB patients and the caregivers were asked about
the travel time and expenses associated with visits to HEWs in the
health post to take drugs. This included transport, food and other
costs. The cost data was collected for all caregivers who
accompanied the patients to health centres and health posts.
Travel time was estimated from the patient’s home to the health
post in the kebele. The time costs were converted to a monetary
value based on unskilled wage rates [18] which was US$1.39 per
day (US$0.17 per hour) in the study area.
The cost data was case specific for all study participants and was
standard in each arm of the intervention. At least ten visits in the
intensive phase and six visits in the continuation phase were used
as a standard for smear-positive patients and care givers for both
the CDOT and HFDOT.
For each treatment option, average costs were multiplied by the
number of times each cost was incurred to calculate the cost per
patient successfully treated. For each kebele, we calculated
summary values of costs and then used an independent sample t
test, weighted by cluster size, to compare the mean costs using
kebele as a unit of analysis.
The data sources were budget and expense files of the districts
finance and health offices, health facilities, health workers’
payroll, drug and supply prices, funds used from research
projects (training, supervision and review of activities), TB
control programme, bank reports and interview of the study
participants.
Effectiveness
The measure of effectiveness was based on sputum smear
results at the end of the 2nd, 5th, and 7th months of treatment.
Patients with at least two negative smears including the smear at
the 7th month were reported as cured. Patients who finished the
treatment but did not have the 7th month smear result were
reported as treatment completed. We used TSR as a measure of
effectiveness, which is a standard indicator used by WHO to
TB Treatment Cost in Ethiopia
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measure programme success and which has been adopted by the
NTLCP in Ethiopia. TSR was calculated as the sum of the
number of TB patients who were cured and the number of TB
patients for which treatment was completed divided by the total
number of smear-positive cases reported, expressed as a
percentage [1,5]. The effectiveness data was obtained from
CRT. Briefly, we calculated the summary values of TSRs for
each kebele. Then we used an independent sample t test,
weighted by cluster size, to compare the mean TSR using the
kebele as a unit of analysis. This is robust for cluster level analysis
of binary outcomes [20].
In a no intervention scenario (‘‘do-nothing alternative’’), a self-
cure rate of 20% was used but 0% for HIV infected TB patients.
The reported rate of TB-HIV co-infection in southern Ethiopia
was 17.5% [21]. The self-cure rate was calculated using the
following formula: [(estimated percentage of HIV+ patients x 0) +
(estimated percentage of TB patients who are not HIV infected x
20)]/100 [22].
Cost-Effectiveness
Cost-effectiveness was calculated as the average cost per patient
treated successfully. This was done by dividing the total cost by the
number of TB patients successfully treated for each of the two
treatment options, the CDOT and HFDOT.
Sensitivity Analysis
Sensitivity analysis determines the level of uncertainty in the
components of the evaluation by repeating the comparison
between cost items and consequences while varying the assump-
tions underlying the estimates. A one-way sensitivity analysis varies
one cost item at a time while others are held at base value to
measure its impact on the results of the evaluation [18,23]. We
performed one-way sensitivity analysis to assess the robustness of
the results to changes in the cost values. We varied one cost
variable at a time, repeating the analysis for the cost items. We
based the uncertainty analyses on the minimum and maximum
values of mean travel time, transport and total cost in our study.
We used the 95% confidence interval of the effectiveness for the
treatment outcome.
Ethical Clearance
The Ethical Review Committee of Southern Nations, Nation-
alities and Peoples’ Regional Health Bureau approved the study.
We first discussed the aim of the study with the TB programme
managers and kebele leaders about community- based TB care
and obtained permission to proceed. Then we explained the aim
of the study to the study participants and enrolled them after
obtaining informed consent. The study participants were also
informed about the right to refuse or withdraw from the study.
The Ethical Review Committee approved verbal consent, in
adherence to NTLCP recommendations.
Results
Two hundred and twenty-nine smear-positive patients were
enrolled. We interviewed 161smear-positive patients and 113 care
givers in the CDOT and 68 smear-positive patients and 97
caregivers in HFDOT. More women were enrolled in CDOT
62% (99 of 161 patients) than HFDOT 37% (25/68). Regarding
literacy, 63% of the patients (93/148) from community and 55%
(33/60) from facility were literate. Regarding marital status, 63%
patients (93/148) from community and 71% (47/66) from facility
were married (Table 1).
Costs
Programme costs: the health service and health extension
workers costs. The health service invested US$73.5 for
HFDOT and US$7.9 for CDOT. The cost of anti-TB drugs for
a patient was US$22.1. The cost of training was US$10.0 in
HFDOT and US$5.1in CDOT. Similarly, the cost of supervision
was US$10.9 in HFDOT and US$5.9 in CDOT.
The travel time (estimated travel cost) for HEWs was 19.7 hours
(US$5.1). The transport and food costs were US$0.9 and US$2.8,
respectively. Therefore, the HEWs total cost per patient was
US$8.8, accounting for 14.3% of the total cost per patient for
CDOT.
Patient costs: the patient and caregiver costs. The
patient costs are described as follows. The mean and standard
deviation (SD) of travel time (estimated travel cost) was 27.6
hours (US$4.3, SD=1.9) in CDOT and 68.9 hours (US$11.9,
SD= 5.2) in HFDOT (p,0.05). The transport cost was US$0.6
(SD=1.2) in CDOT and US$3.7 (SD=10.5) in HFDOT
(p= 0.013). Similarly, the associated food cost was (US$3.5,
SD= 2.9) in CDOT and US$8.8 (SD=5.2) in HFDOT. The
direct patient cost was lower in CDOT (US$4.1, SD=3.0) than
HFDOT (US$12.1, SD=10.7) (p,0.05). The total patient cost
was lower in CDOT (US$8.4, SD= 3.9) than HFDOT (US$24.4,
SD= 12.2) (p,0.05). The total cost in CDOT was lower than HF
DOT by 63.9% (Figure 1).
The caregiver costs are described as follows. The travel time
(estimated travel cost) was 9.9 hours (US$1.6, SD=1.5) in CDOT
Table 1. Baseline characteristics of smear-positive
tuberculosis patients in Southern Ethiopia.
Variable Community DOT Health facility DOT
Mean age (SD) 26.8 (13.7) 25.2 (11.8)
Gender
Men 62 (38.5%) 43 (63.2%)
Women 99 (61.5%) 25 (36.8%)
Education
Illiterate 55 (37.2%) 27 (45.0%)
Literate 93 (62.8%) 33 (55.0%)
Missing 13 8
Occupation
Student 38 (32.2%) 16 (26.7%)
Farmer 34 (28.8%) 24 (40.0%)
Housewife 38 (32.2%) 18 (30.0%)
Others 8 (6.8%) 2 (3.3%)
Missing 42 8
Marital status
Single 51 (34.5%) 19 (28.8%)
Married 93 (62.8%) 47 (71.2%)
Widowed/divorced 4 (2.7%) 0 (0.0%)
Treatment outcome*
Cured 132 (82.0%) 56 (82.4%)
Treatment completed 29 (18.0%) 12 (17.6%)
*A smear-positive tuberculosis patient with at least two negative smears
including that at 7th month was reported as cured, while a patient who finished
the treatment but did not have the 7th month smear result was reported as
treatment completed.
doi:10.1371/journal.pone.0009158.t001
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and 16.5 hours (US$4.7, SD=5.7) in HFDOT (p,0.05). The
transport cost was lower in CDOT (US$0.1, SD=0.9) than
HFDOT (US$14.2, SD=43.6) (p = 0.006). Similarly the associat-
ed food cost was lower in CDOT (US$0.8, SD=1.2) than
HFDOT (US$2.1, SD=2.8) (p,0.05). The total caregiver cost
was lower in CDOT (US$2.5, SD=2.7) than HFDOT (US$21.1,
SD=50.6) (p = 0.002). The total care giver cost in CDOT was
lower than HF DOT by 88.2% (Figure 2).
The total cost (patient and programme cost) per successfully
treated smear-positive patient was higher in HFDOT (US$161.9)
compared to CDOT (US$60.7). The total cost in CDOT was
lower than HF DOT by 62.6% (Table 2 and figure 3).
Effectiveness
In the CRT, smear-positive patients received DOT, 230 under
HEWs in the community and 88 under GHWs in health facilities.
In the community-based approach, of the 230 patients, 172
(74?8%) were cured and 33 (14?3%) completed treatment. Of the
88 patients treated in the health facilities, 60 (68?2%) were cured
and 14 (15?9%) completed treatment. The mean TSR was higher
in CDOT (89.3%) than HFDOT (83?1%). The mean and its
difference being 6.2% (1.4% - 10.9%, p= 0?012). The details are
given elsewhere [17]. Based on the reported 17.5% TB-HIV co-
infection rate in smear-positive patients in Southern Ethiopia [21]
and using the formula to calculate self-cure, cure without
treatment (given above in the methods section under ‘effective-
ness’), we found TSR of 80.8% for HFDOT and 86.9% for
CDOT.
Cost-Effectiveness
The cost per successfully treated patient was US$161.9 and
US$60.7 in HFDOT and CDOT, respectively. CDOT reduced
the total cost per successfully treated patient by 62.6% (Table 2
and figure 3). Based on the cost and effect estimates of no
intervention (US$0, 17%), HFDOT (US$161.9, 83.1%) and
CDOT (US$60.7, 89.3%), the incremental cost-effectiveness ratio
of running HFDOT and CDOT from a do-nothing alternative
was 2.4 and 0.8, respectively. The incremental cost-effectiveness
ratio of HFDOT to CDOT was -16.3.
Sensitivity Analysis
The sensitivity analysis showed CDOT to be a more effective
and less costly approach compared to HFDOT on varying
estimates of the main cost items (Table 3).
Discussion
Interpretations and Overall Evidence
In Ethiopia, DOTS coverage was reported to be 100%
(implemented in all hospitals and health centres). However, case
finding and TSRs are below the WHO targets [1]. In such a
setting, it is relevant to ask how this could be improved.
Improvement may be achieved by more efficient intervention for
identifying TB cases, including providing treatment at a lower cost
[24]. In our study, the cost of treating a patient in health facilities
was 2.7 times higher than the cost of treating a patient in the
community-based approach inclusive of the initial investment for
implementation, training and supervision of CDOT. CDOT
improved the TSR by 6.2% and reduced the cost of treating a
patient by 62.6%. This shows that more patients could be
successfully treated with the same amount of resources by using
CDOT instead of HFDOT.
The main reason for the reduction in cost of the community-
based approach was the reduction in the travel distance and
related costs as the patients visited the HEWs in the health post,
which was located nearer to where the patients lived. The
reduction in caregiver and patient costs results in a slight increase
over the health service cost. However, from a societal perspective,
the gain in terms of cost and health benefits is huge. Thus,
involving HEWs in TB treatment is an attractive economic option
to the health service and to the patients and their caregivers.
Decentralization of the DOTS programme improves the TSR
[25,26]. A community-based approach is found to be more
effective and cost-effective as it overcomes the limitation of
reliance on health facilities in providing access to TB care
[27,28,29]. It also consistently reduces the cost of treatment even
in a decentralized health service [16]. In our study, the cost per
successfully treated patient was low (US$61) compared with studies
from Malawi (US$201) and Botswana (US$1657). Similarly, the
reduction in average cost per patient treated in our study was 63%
compared to those reported for South Africa (36%) and Kenya
(65%) [11,12,13,14]. The main reason could be that Ethiopia is a
low-cost country with low salaries. Also, we did our study in a rural
setting as opposed to an urban setting.
The gain in effectiveness of the CDOT was mainly due to the
reduced travel distance that reduced the cost, and time lost on
travel to receive treatment. In settings with low health service
coverage the significance of CDOT is high. CDOT could
complement the existing health service to improve the access
and success rate TB programmes in countries like Ethiopia where
CDOT has not yet been implemented on a national scale.
The strength of the study is that the data was prospectively
collected in CRT. We adhered to the routine care for treatment and
Figure 1. Tuberculosis patient costs under DOT options. Blue
bar - Health facility DOT. Red bar - Community DOT.
doi:10.1371/journal.pone.0009158.g001
Figure 2. Caregiver costs under DOT options. Blue bar - Health
facility DOT. Red bar - Community DOT.
doi:10.1371/journal.pone.0009158.g002
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outcome measures as recommended by the NTLCP, which did not
require extra visits by the patients because of the community-based
approach. We used HEWs living in the kebeles, who were employed
to provide a health service that favoured the sustainability of the
community approach in the Ethiopian health system as opposed to
other community approaches whereby the community health
workers have been used for only short periods. We conducted our
intervention under approved programme conditions and prospec-
tively collected cost data that reduced the chance of recall bias. We
included all cost categories in the sensitivity analysis that reduced the
chance of selection bias. Moreover, the long period of the observation
(September 2006 to April 2008, i.e., 20 months) may have
contributed to the consistency of the data [18]. In our study we did
not have drop outs of HEWs due to the fact that HEWs were selected
from the kebeles they live in. However, in the future, the possibility of
training new HEWs and providing refresher training to the already
trained HEWs should be considered. This also applies to the general
health workers involved in TB control in health centres and hospitals
that have higher drop outs. Therefore, the estimated cost required for
CDOT will still remain lower than HFDOT for similar outcomes.
The government of Ethiopia has already increased the uptake
and training of HEWs in the country to ensure and deploy two
HEWS per kebele. Thus, doubling HEWs per kebele has already
started at the end of the first year of the intervention in 2007
before drop outs occur at least in our study area. Therefore, it only
requires training HEWs which was two days in case of our study to
enrol them in community based TB control activities to achieve
the outcomes reported in our intervention.
A major limitation of the study was that we based our estimation
on the time converted into monetary value for which there is no
Figure 3. Costs per successfully treated smear-positive tuberculosis patient. Blue bar - Health facility DOT. Red bar - Community DOT.
doi:10.1371/journal.pone.0009158.g003
Table 2. Average cost per patient for treatment options of smear-positive tuberculosis patients in Southern Ethiopia 2006/07.
Cost items Community DOT Health facility DOT
quantity mean unit price in US$ quantity mean unit price in US$
Programme costs
Running TB programme 1 7.9 1 73.5
Training and review meeting 1 5.1 1 10.0
Drugs and supplies 1 22.1 1 22.1
Supervision 8 5.9 3 10.9
Health extension workers cost
Direct cost of visit 8 3.7
Indirect cost 8 5.1
Total programme cost 49.8 116.5
Patient costs
TB patient
Direct cost of visits* 66 4.1 66 12.5
Indirect cost 4.3 11.9
Caregiver
Direct cost 0.9 16.3
Indirect cost 1.6 4.7
Total patient costs 10.9 45.4
Total costs 60.7 161.9
*Patients visited the health facilities in health facility DOT and health posts in community DOT. Health extension workers visited the health facilities monthly to collect
drugs. Direct cost implies out-of- pocket expenses and indirect cost implies travel time cost.
doi:10.1371/journal.pone.0009158.t002
TB Treatment Cost in Ethiopia
PLoS ONE | www.plosone.org 5 February 2010 | Volume 5 | Issue 2 | e9158
agreement among experts [18]. It was also difficult to get reliable
income data for rural areas. Therefore, we based our estimate on
the wage of unskilled labour. This might have underestimated the
time cost. In treatment outcomes like deaths and defaulters the cost
was not captured for the total follow up period due to the nature of
the outcome. In such cases, the distance from the health institutions
and the related high cost could be the plausible explanations for
such outcomes mainly in HFDOT. Therefore, the cost of treating
smear-positive patient could be on the lower side, an underestimate,
in both arms but mainly in HFDOTwhere distance and related cost
was high. Using one-way sensitivity analysis, where we varied one
cost item at a time, might not have captured the interaction between
cost items. The economic and public health benefit of treating TB
patients in terms of disease transmission, averting death or
increasing productivity was not the scope of the study.
Generalizability
Our study area was a densely populated agrarian community in
Ethiopia. This area is typical of the rural population of Ethiopia,
representing 85% of the total population where, high treatment
success rates are not achieved because of the limited health service
coverage and shortage of health workers. With health posts in each
kebele and the huge number of HEWs, more cost-effective
approaches are needed. As opposed to the study period where
there was only one HEW per kebele, now two HEWs are deployed
to rural kebeles in Ethiopia. Thus, we believe that our findings are
applicable in similar settings. For example our approach could be
adopted in other regions or countries where two HEWs work in
each rural kebele. In addition, the Federal Ministry of Health of
Ethiopia has assigned full-time public health nurses as supervisors
of HEWs that favour implementation of CDOT. We presented the
results of the study at a NTLCP review meeting.
In conclusion, community DOT costs only 37% of what
HFDOT costs for similar outcomes. For the same amount of
money in health facilities, at least two smear-positive patients
could be treated under a community-based approach. There are
both economic and public health reasons to consider involving
HEWs in TB treatment by the NTLCP of Ethiopia. However, due
attention should be paid to ensuring initial start up investment to
implement CDOT, training and supervision.
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